Since 2007, the Administrative Core has deftly identified and accomplished tasks related to the operation and success of this P01 through two granting cycles. This experience will be leveraged in the next granting cycle to permit the P01 leadership to again use the Administrative Core as the primary means to assure continuous integration and interaction among all P01 components and to oversee the research projects and other cores. This Core facilitates rapid communication and connection among investigators, projects, and cores through face-to-face meetings, written reports, and electronic communication. This Core assists sharing our research data with investigators both within and outside of Memorial Sloan Kettering (MSK) with a special emphasis to link Dr. Lovly and her Project 3 team at Vanderbilt with all facets of the program project through electronic communication and videoconferencing. The Administrative Core provides (1) administrative services; regulatory and reporting services, including preparation of annual reports and renewals; (2) budget management; (3) publication management and oversight; (4) videoconferencing for all P01 activities; (6) scheduling of P01 work-in-progress conferences for the investigators and yearly face-to-face presentations to our advisory committees; and (6) support of the oversight activities of the Executive and Advisory committees. The Administrative Core centralizes, expands, and improves the operational capabilities of the individual research projects and cores, avoids duplication, and ensures optimum utilization of resources. The MSK Lung P01 Program Manager supported by this Core meets at least 4 times a year with the Principal Investigators and the Executive Committee to assist in monitoring operations so that the research supported by the program project proceeds efficiently. The MSK Lung P01 Program Manager, with Drs Kris and Ladanyi, prepares and distributes a yearly progress report for the Executive and the Scientific Advisory Committees to assist in their review and oversight. The Administrative Core supports the Project and Core Leaders, the Executive Committee, and the Advisory Committees. It provides services that are essential for the P01 to function as an integrated research program to develop new targets for treatment for persons with lung cancers.
Lung cancers are America?s leading cancer killers, responsible for 158,000 deaths this year. This grant addresses two critical roadblocks to improving the care and curability of persons with these illnesses: understanding how cancers spread (metastasis) and the lack of medicines to prevent spread or to eradicate cancers that have spread from the lungs. The Administrative Core unites, integrates, and evaluates the components of this P01 is critical to this effort.
|Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86|
|Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736|
|Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661|
|Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340|
|Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577|
|Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4|
|Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :|
|Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :|
|Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739|
|Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902|
Showing the most recent 10 out of 188 publications